Bacillus anthracis vaccine based on bacterial-like particles

By displaying Bacillus anthrax antigen fusion protein on the surface of GEM particles, a bacterial-like particle vaccine was prepared, solving the problem of preparing Bacillus anthrax vaccines in the prior art and achieving good immunoprotective effect.

CN118930658APending Publication Date: 2024-11-12ACADEMY OF MILITARY MEDICAL SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411005080.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing technologies are insufficient for the effective preparation of anthrax spore-forming vaccines.

Method used

Bacterial-like particle vaccines were prepared by displaying a fusion protein of Bacillus anthracis antigen on the surface of GEM particles. P60 anchor protein P60 was used to bind to the peptidoglycan of GEM particles to form P60-LFb-GEM and P60-PAD4-GEM particles.

Benefits of technology

The prepared bacterial-like particle vaccine has good immunogenicity and protective properties, and can effectively prevent anthrax spore infection, showing a significant immune protective effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004962794200000011
    Figure HDA0004962794200000011
  • Figure HDA0004962794200000012
    Figure HDA0004962794200000012
  • Figure HDA0004962794200000021
    Figure HDA0004962794200000021
Patent Text Reader

Abstract

The invention discloses a bacillus anthracis vaccine based on bacterial-like particles. The invention belongs to the field of biological medicine, and relates to a bacillus anthracis vaccine based on bacterial-like particles. A fusion protein containing a bacillus anthracis antigen is displayed on the surface of a GEM particle to prepare the bacterium-like particle, wherein the fusion protein containing the bacillus anthracis antigen is a fusion protein A or a fusion protein B, wherein the fusion protein A is formed by fusing an ankyrin P60 and a fourth structural domain PAD4 of a PA protein of the bacillus anthracis; the fusion protein B is formed by fusing an ankyrin P60 and a fourth structural domain PAD4 of a PA protein of the bacillus anthracis; and the fusion protein B is formed by fusing ankyrin P60 and a PA binding structural domain LFb of a lethal factor LF of bacillus anthracis. The bacterium-like particles can be used for preparing candidate vaccines, after mice are immunized by the bacterium-like particles, the mice can be stimulated to generate specific IgG and IgA responses to PAD4 and LFb, and the mice can be protected against challenge of bacillus anthracis vaccine strains.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine and relates to an anthrax bacillus vaccine based on bacteria-like particles. Background Art

[0002] Lactococcus lactis can be treated with hot acid to remove all intracellular components including nucleic acids, but the cell wall peptidoglycan matrix can be preserved intact. Therefore, the inactivated particles obtained still maintain the same size and shape as the bacteria before treatment, which are called bacteria-like particles (BLP), or Gram positive enhancer matrix (GEM). The bacteria-like particle system has been developed into a new vaccine antigen delivery system for the presentation of vaccine antigens, and the core of the bacteria-like particle vaccine antigen delivery system is the GEM-PA system. The system mainly consists of two parts: the first part is the protein anchor (PA), which contains a peptidoglycan binding sequence and can be non-covalently bound to peptidoglycan; PA has a high affinity for peptidoglycan, and only after SDS or lithium chloride treatment can the PA protein be separated from the peptidoglycan; the second part is the lactic acid bacteria treated with hot trichloroacetic acid, namely the GEM particles, which can efficiently bind to the PA fusion protein. As a good surface display platform, the GEM-PA system is easy to operate. Simply put, PA is fused with the antigen protein for expression, and the protein solution after expression is mixed with the GEM particles for incubation. Under the traction of the anchoring protein PA, the antigen protein can be efficiently bound to the GEM particles. Summary of the invention

[0003] The main problem to be solved by the present invention is how to obtain anthrax bacillus vaccine.

[0004] In order to solve the above problems, the present invention provides bacteria-like particles.

[0005] The bacteria-like particles of the present invention are prepared by displaying a fusion protein containing anthrax bacillus antigen on the surface of GEM particles.

[0006] In the above-mentioned bacteria-like particles, the fusion protein containing Bacillus anthracis antigen is fusion protein A or fusion protein B,

[0007] The fusion protein A is formed by the fusion of the anchor protein P60 and the 4th domain PAD4 of the PA protein of Bacillus anthracis; the fusion protein B is formed by the fusion of the anchor protein P60 and the PA binding domain LFb of the lethal factor LF of Bacillus anthracis.

[0008] Furthermore, the amino acid sequence of the fusion protein A may be any of the following:

[0009] a1) a protein having an amino acid sequence of SEQ ID No. 3;

[0010] a2) a protein having the same function as the amino acid sequence shown in SEQ ID No. 3 after one or more amino acid residues are replaced and / or deleted and / or added;

[0011] a3) a protein having an amino acid sequence of at least 75% identity with any of a1) or (a2) and having the same function;

[0012] a4) A fusion protein A obtained by connecting a tag to the end of any one of the proteins defined in a1) to (a3).

[0013] Furthermore, the amino acid sequence of the fusion protein B may be any of the following:

[0014] b1) the amino acid sequence of the protein is SEQ ID No. 4;

[0015] b2) a protein having the same function as that of the amino acid sequence shown in SEQ ID No. 4 after one or more amino acid residues are replaced and / or deleted and / or added;

[0016] b3) a protein having an amino acid sequence with at least 75% identity with any of b1) or (b2) and having the same function;

[0017] b4) A fusion protein B obtained by connecting a tag to the end of the protein defined in any one of b1) to (b3).

[0018] In order to facilitate purification or detection of the protein in a1) or b1), a tag protein may be connected to the amino terminus or carboxyl terminus of the protein consisting of the amino acid sequence shown in SEQ ID No. 3 or SEQ ID No. 4 in the sequence listing.

[0019] The above proteins can be artificially synthesized, or their encoding genes can be synthesized first and then expressed biologically.

[0020] Furthermore, the fusion protein A is P60-PAD4, and the fusion protein B is P60-LFb.

[0021] The bacteria-like particles may be P60-LFb-GEM or P60-PAD4-GEM. The ratio of P60-PAD4 to GEM particles in the P60-PAD4-GEM may be: 30 μg or more of the P60-PAD4 protein corresponds to one unit of GEM particles (2.5×10 9The ratio of the P60-LFb to the GEM particles in the P60-LFb-GEM can be: 30 μg or more of the P60-LFb protein corresponds to one unit of GEM particles (2.5×10 9 indivual).

[0022] The tag protein includes but is not limited to: GST (glutathione sulfhydryltransferase) tag protein, His6 tag protein (His-tag), MBP (maltose binding protein) tag protein, Flag tag protein, SUMO tag protein, HA tag protein, Myc tag protein, eGFP (enhanced green fluorescent protein), eCFP (enhanced cyan fluorescent protein), eYFP (enhanced yellow-green fluorescent protein), mCherry (monomeric red fluorescent protein) or AviTag tag protein.

[0023] A person skilled in the art can easily adopt known methods, such as directed evolution or point mutation, to mutate the nucleotide sequence encoding fusion protein A or fusion protein B of the present invention. Those artificially modified nucleotides having 75% or more identity with the nucleotide sequence of fusion protein A or fusion protein B isolated from the present invention are all derived from the nucleotide sequence of the present invention and are equivalent to the sequence of the present invention as long as they encode fusion protein A or fusion protein B and have the function of fusion protein A or fusion protein B.

[0024] The aforementioned 75% or more identity may be 80%, 85%, 90% or 95% or more identity.

[0025] Herein, identity refers to the identity of an amino acid sequence or a nucleotide sequence. The identity of an amino acid sequence or a nucleotide sequence can be determined using a homology search site on the Internet, such as the BLAST webpage on the NCBI homepage website. For example, in Advanced BLAST2.1, by using blastp as a program, setting the Expect value to 10, setting all Filters to OFF, using BLOSUM62 as a Matrix, setting Gap existence cost, Per residue gap cost and Lambda ratio to 11, 1 and 0.85 (default values) respectively and searching for a pair of amino acid sequences or nucleotide sequences to calculate the identity, then the value (%) of the identity can be obtained.

[0026] Herein, the 80% or greater identity may be at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity.

[0027] Herein, the 90% or greater identity may be at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity.

[0028] Furthermore, the anchor protein P60 is derived from Listeria monocytogenes.

[0029] The amino acid sequence of the anchor protein P60 may be from position 1 to position 218 in sequence 3 or from position 1 to position 218 in sequence 4 in the sequence list.

[0030] The fusion protein in the bacteria-like particles described above also falls within the scope of protection claimed by the present invention.

[0031] The present invention also provides the use of the above-mentioned bacteria-like particles in the preparation of anthrax Bacillus vaccine.

[0032] The present invention also provides the use of the fusion protein described above in the preparation of anthrax Bacillus vaccine. The encoding nucleotide of the fusion protein A may be as follows:

[0033] c1) the nucleotide sequence is the DNA molecule shown in SEQ ID No.1;

[0034] c2) a DNA molecule that has 90% or more identity with the nucleotide sequence defined in c1) and encodes the fusion protein A described above;

[0035] c3) A DNA molecule that hybridizes with the nucleotide sequence defined in c1) or c2) under stringent conditions and encodes the fusion protein A described above.

[0036] The encoding nucleotide of the fusion protein B may be as follows:

[0037] d1) the nucleotide sequence is the DNA molecule shown in SEQ ID No.2;

[0038] d2) a DNA molecule having 90% or more identity with the nucleotide sequence defined in d1) and encoding the fusion protein B described above;

[0039] d3) A DNA molecule that hybridizes with the nucleotide sequence defined in d1) or d2) under stringent conditions and encodes the fusion protein B described above.

[0040] The present invention also provides an anthrax Bacillus vaccine, wherein the active ingredients of the vaccine include the bacteria-like particles described above.

[0041] In the present invention, the vaccine active ingredient includes any one of a polypeptide vaccine and a protein vaccine.

[0042] The vaccine preparation comprises any one of oral vaccines, intravenous vaccines, arterial vaccines, mucosal vaccines, intramuscular vaccines, subcutaneous vaccines, organ vaccines and intrathoracic and abdominal vaccines, or a combination of at least two of them.

[0043] In the present invention, the active ingredient in the vaccine may specifically be the bacteria-like particles P60-LFb-GEM or P60-PAD4-GEM.

[0044] The P60-LFb-GEM and P60-PAD4-GEM were mixed at a ratio of 1:1, and the GEM concentration was 100 U / ml.

[0045] In the present invention, the GEM is GEM particles obtained by treating Lactococcus lactis 1936 bacteria with 10% trichloroacetic acid.

[0046] The present invention also provides the use of the above-mentioned bacteria-like particles, or the above-mentioned fusion protein, or the above-mentioned Bacillus anthracis vaccine in the preparation of a drug for treating or preventing a disease infected with Bacillus anthracis.

[0047] The present invention utilizes the peptidoglycan binding domain of the P60 protein from Listeria monocytogenes and fuses the antigenic protein of Bacillus anthracis to construct a Bacillus anthracis vaccine based on bacteria-like particles. Experiments show that the Bacillus anthracis vaccine of the present invention has good immunogenicity and protection, and can be used for the research and development of new anthrax vaccines. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Figure 1 The expression of P60 fusion protein in E. coli BL21 (DE3), wherein lane 1: BL21 (DE3) control; lane 2: fusion protein P60-PAD4; lane 3: fusion protein P60-LFb.

[0049] Figure 2 This is the analysis of the binding of P60 fusion protein to GEM particles, where lane 1: empty GEM; lane 2: P60-LFb-GEM; lane 3: P60-PAD4-GEM.

[0050] Figure 3 ELISA was used to detect the antibody titer in mouse serum.

[0051] Figure 4 ELISA was used to detect sIgA in mouse lung wash fluid.

[0052] Figure 5 The above figure shows the result of the challenge experiment. The challenge dose is 20LD. 50; The corresponding attack dose in the figure below is 50LD 50 ). DETAILED DESCRIPTION

[0053] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.

[0054] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.

[0055] Unless otherwise specified, the quantitative tests in the following examples were performed three times and the results were averaged.

[0056] The pET28a plasmid in the following example has been recorded in: Wei Ying et al., Expression and functional analysis of the laminin binding protein Lsa20 of Leptospira, Biotechnology Letters, 2015, 26((4): 481-484. The public can obtain the biological material from the applicant. The biological material is only used to repeat the experiment of the present invention and cannot be used for other purposes.

[0057] The lactococcus lactis 1936 in the following examples has been recorded in: Su Runyu, Preliminary Study on GEM Granular Vaccine of Melioidosis, Dissertation, Tianjin Agricultural College. The public can obtain the biological material from the applicant, and the biological material is only used for repeating the experiment of the present invention and cannot be used for other purposes.

[0058] The anthrax Bacillus Pasteur II vaccine strain in the following examples has been recorded in: Zhailina et al, Inhalable vaccine of bacterial culture supernatant extract mediates protection against fatal pulmonary anthrax. Emerging Microbes & Infections. 2023, 12: 1, 2191741. The public can obtain the biological material from the applicant, and the biological material is only used for repeating the experiments of the present invention and cannot be used for other purposes.

[0059] The C57BL / 6J mice in the following examples were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd.

[0060] The following examples used GraphPad Prism 9.0 software to process the data, and the experimental results were expressed as mean ± standard deviation. One-way ANOVA test was used, and P < 0.001 (***) indicated a very significant difference.

[0061] Example 1. Expression of P60-PA4D and P60-LFb fusion proteins

[0062] 1. Target gene design and synthesis

[0063] The fourth domain PAD4 of the anthrax protective antigen PA protein and the PA binding domain LFb of the lethal factor LF were selected as target antigens, and the peptidoglycan binding domain of the P60 protein from Listeria monocytogenes was used as an anchor motif to design a fusion protein for constructing a target antigen protein that can bind to the surface of GEM particles. Then, according to the genome information of the anthrax spore strain A16R and the sequence information of the P60 protein encoding gene in the network database, a fusion gene fragment ((encoding P60-PAD4 and P60-LFb, respectively) was designed and synthesized by Anhui General Bio. The nucleotide sequence of the P60-PAD4 fusion gene fragment is sequence 1 in the sequence list, encoding a fusion protein A with an amino acid sequence of sequence 3 ((referred to as fusion protein P60-PAD4), and the nucleotide sequence of the P60-LFb fusion gene fragment is sequence 2 in the sequence list, encoding a fusion protein B with an amino acid sequence of sequence 4 (referred to as fusion protein P60-LFb).

[0064] 2. Construction of recombinant plasmid

[0065] The pET28a plasmid was double-digested with restriction endonucleases NdeⅠ and BamHI, and then purified and recovered using a DNA gel recovery kit. The fusion protein encoding gene fragments P60-PAD4 and P60-LFb were double-digested with restriction endonucleases NdeⅠ and BamHI, purified and recovered, and connected with the plasmid pET28a that was also digested with the same enzymes, and transformed into DH5α. After the transformation, 200μl of bacterial solution was evenly spread on the kanamycin resistance plate, and incubated in an incubator at 37℃ for 16h. The growth of the kanamycin resistance plate colonies was observed, and the correct transformants were screened by PCR.

[0066] 3. Construction of recombinant bacteria. Pick several single colonies from the kanamycin plate into a 5 ml LB test tube (containing 50 μg / ml kanamycin), shake and culture for about 12 hours, extract the plasmid for PCR verification, and send the positive clones for sequencing to obtain the correctly sequenced recombinant plasmids pET-P60-PAD4 and pET-P60-LFb.

[0067] The structure of the recombinant plasmid pET-P60-PAD4 is described as follows: a recombinant vector obtained by replacing the fragment between the NdeⅠ and BamHI recognition sites of the pET28a plasmid with the DNA molecule shown in SEQ ID No.1 while keeping the other nucleotides of the pET28a plasmid unchanged.

[0068] The structure of the recombinant plasmid pET-P60-LFb is described as follows: a recombinant vector obtained by replacing the fragment between the NdeⅠ and BamHI recognition sites of the pET28a plasmid with the DNA molecule shown in SEQ ID No.2 while keeping the other nucleotides of the pET28a plasmid unchanged.

[0069] 3 μl of the correctly sequenced plasmids pET-P60-PAD4 and pET-P60-LFb were transformed into Escherichia coli BL21 (DE3) (purchased from Beijing Quanshijin Biotechnology Co., Ltd., catalog number CD601-02), and the specific operation steps were the same as above. Pick a single colony from the kanamycin-resistant plate in a 5 ml LB test tube (containing kanamycin at a concentration of 50 μg / ml), shake and culture for about 12 hours, and use a final concentration of 15% sterile glycerol to preserve the strain for later use. The recombinant bacteria were named BL21 (pET-P60-PAD4) and BL21 (pET-P60-LFb).

[0070] 4. Induced expression of recombinant fusion protein. Pick the above-mentioned BL21 (pET-P60-PAD4) and BL21 (pET-P60-LFb) recombinant bacterial single colonies respectively, place them in 5 ml LB medium containing Kan resistance (kanamycin concentration is 50 μg / m), and culture at 37°C, 220 rpm overnight with shaking. The next day, transfer 400 ml of fresh Kan+LB medium at a ratio of 1%, and culture at 37°C, 220 rpm with shaking for 4 hours. Add IPTG with a final concentration of 1 mmol / L, and induce at 16°C overnight. Collect the bacteria by centrifugation at 8000 rpm and 4°C, wash with PBS, resuspend the bacteria in 30 ml (PBS, and break the cells by low-temperature ultrasound. The ultrasound intensity is 35%, ultrasound for 30 (min, and pause for 5 (s every 5 (s of ultrasound. Centrifuge at 12000 rpm for 10 min, collect the ultrasound supernatant, and identify the expression of the recombinant protein by SDS-PAGE. The results are as follows: Figure 1 Both recombinant fusion proteins P60-PAD4 and P60-LFb can be expressed in Escherichia coli, and their sizes are basically consistent with the theoretical values, so they can be used for the next step of combining with Lactococcus lactis GEM particles.

[0071] Example 2, Lactococcus lactis 1936 (GEM particle preparation and protein binding

[0072] 1. Streak culture of Lactococcus lactis 1936 to isolate single colonies. Inoculate Lactococcus lactis 1936 into fresh 5 ml (M17 broth medium (purchased from Qingdao High-tech Industrial Park Haibo Biotechnology Co., Ltd., item number: HB0391) and incubate at 30°C for 24 hours. Transfer to 400 ml (M17 medium and incubate at 30°C for 24 hours. Take 5 ml of the cultured bacteria and measure the OD 600 At the same time, the remaining culture was measured in volume and centrifuged.

[0073] The cells were collected by centrifugation at 8000 rpm for 15 min in a sterile bottle and washed twice with 1-fold volume of sterilized PBS. 1 ml was taken for viable cell counting.

[0074] 2. The Lactococcus lactis 1936 cells collected by centrifugation were resuspended in 40 ml (10% trichloroacetic acid), boiled for 30 min, centrifuged at 12000 rpm for 10 min to remove the trichloroacetic acid solution, washed three times with 1× PBS to fully remove the residual trichloroacetic acid, and finally resuspended with an appropriate amount of PBS and packaged. The resuspension volume was calculated based on the counting results and the volume was calculated as 2.5×10 9 The product is 1 unit (1U), packaged at 100U / ml to obtain GEM particles that can be used for protein antigen binding, and stored at -70°C for future use.

[0075] 3. Take out the prepared Lactococcus lactis 1936-GEM particles, combine 1U of GEM particles with 1ml of supernatant containing fusion protein P60-PAD4 and P60-LFb bacterial cell ultrasonic disruption (obtained in Example 1, wherein the content of P60-PAD4 or P60-LFb is greater than 30μg / ml), incubate at room temperature with slow rotation for 30min, collect the combined GEM particles by centrifugation, wash 3 times with PBS to remove the fusion protein not bound to the surface of GEM particles, resuspend in PBS, and identify the binding effect by SDS-PAGE.

[0076] The results are as follows Figure 2 As shown, the expressed recombinant antigen protein can bind to GEM particles to form bacterial-like particles P60-LFb-GEM and P60-PAD4-GEM, which can be studied as candidate vaccines. When preparing the vaccine, the amount of GEM and protein can be increased according to the amount required for the immune experiment.

[0077] Example 3: Immunological evaluation of bacterial-like particle anthrax vaccine

[0078] 1. Vaccine immunogenicity evaluation

[0079] The P60-LFb-GEM and P60-PAD4-GEM samples prepared earlier were mixed in a ratio of 1:1. At this time, the GEM concentration was still 100 U / ml. The mixture of the two was used as a candidate for the next step of vaccine research.

[0080] Mice were immunized by intranasal drops. The immunization dose was based on the amount of GEM particles. According to relevant literature, the dose was set as 1U / mouse. There were 6 mice in each group. C57BL / 6J mice (female) were immunized by intranasal drops using isoflurane respiratory anesthesia. Each mouse was immunized by intranasal drops of 10μl (diluted according to the dose); GEM particles without protein binding (referred to as empty GEM particles) resuspended in PBS buffer were used as the negative control group. Mice were immunized by intranasal drops at an immunization dose of 1U / mouse, that is, 10(μl(GEM empty particles). Mice were immunized once every 14 days, for a total of three immunizations. Serum and lung wash samples of mice were collected 10 days after immunization, and the serum specific antibody level and specific sIgA level were detected by ELISA. The coated antigens of the ELISA experiment were purified PA4D and LFb proteins expressed by Escherichia coli. The specific indirect ELISA method was carried out according to the reference (Su Runyu, Preliminary study on GEM particle vaccine for melioidosis, degree thesis, Tianjin Agricultural College).

[0081] The results of the immune assessment were Figure 3 and Figure 4 As shown, compared with the GEM particle control group, the experimental animals in the vaccine group specifically produced IgG antibodies and sIgA antibodies against PA4D and LFb, indicating that after immunization with the bacterial-like particle anthrax vaccine, the experimental animals can be stimulated to produce IgG and sIgA responses against the target antigens, among which the ELISA titer of IgG antibodies was about 1:16000, indicating that the vaccine has good immunogenicity.

[0082] 2. Evaluation of immune protection

[0083] C57BL / 6J mice (female, 6-8 weeks old, weighing about 20-24g) were randomly divided into a vaccine immunization group and a GEM control group, with 10 mice in each group immunized according to the above immunization schedule. Ten days after the third immunization, spores of Bacillus anthracis Pasteur II vaccine strain (referred to as Pasteur strain) were used for challenge.

[0084] The specific method is: Pasteur anthrax spores are diluted to 5×10 8 ( CFU / ml, and the challenge dose for each mouse was 4×10 6 (CFU, 1×10 7( CFU, the corresponding challenge dose is 20LD 50 and 50LD 50Then, the mice were intubated and the anthrax Pasteur (Ⅱ strain was delivered to the lungs using a handheld liquid lung delivery device. The mice were observed, their survival was recorded, and a survival curve was drawn to evaluate the immune protection effect.

[0085] The results are as follows Figure 5 As shown in the figure, it can be seen that under the experimental conditions, for 20LD 50 The protection rate of Pasteur II spore challenge was 100%, against 50LD 50 The immune protection effect of the challenge dose also reached 90%, indicating that the bacterial-like granules (a 1:1 mixture of P60-LFb-GEM and P60-PAD4-GEM particles) produced a good immune protection effect as an anthrax vaccine and was able to protect mice against the attack of weak anthrax strains.

[0086] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.

Claims

1. Bacteria-like particles, characterized in that It is prepared by displaying a fusion protein containing anthrax Bacillus antigen on the surface of GEM particles.

2. The bacteria-like particle according to claim 1, characterized in that The fusion protein containing Bacillus anthracis antigen is fusion protein A or fusion protein B: The fusion protein A is formed by the fusion of the anchor protein P60 and the 4th domain PAD4 of the PA protein of Bacillus anthracis; the fusion protein B is formed by the fusion of the anchor protein P60 and the PA binding domain LFb of the lethal factor LF of Bacillus anthracis.

3. The bacteria-like particle according to claim 1 or 2, characterized in that The amino acid sequence of the fusion protein A is any of the following: a1) a protein having an amino acid sequence of SEQ ID No. 3; a2) a protein having the same function as the amino acid sequence shown in SEQ ID No. 3 after one or more amino acid residues are replaced and / or deleted and / or added; a3) a protein having an amino acid sequence of at least 75% identity with any of a1) or (a2) and having the same function; a4) A fusion protein A obtained by connecting a tag to the end of any one of the proteins defined in a1) to (a3).

4. The bacteria-like particle according to claim 1 or 2, characterized in that The amino acid sequence of the fusion protein B is any of the following: b1) the amino acid sequence of the protein is SEQ ID No. 4; b2) a protein having the same function as that of the amino acid sequence shown in SEQ ID No. 4 after one or more amino acid residues are replaced and / or deleted and / or added; b3) a protein having an amino acid sequence with at least 75% identity with any of b1) or (b2) and having the same function; b4) A fusion protein B obtained by connecting a tag to the end of the protein defined in any one of b1) to (b3).

5. The bacteria-like particle according to any one of claims 1 to 4, characterized in that: The anchor protein P60 is derived from Listeria monocytogenes. The fusion protein in the bacteria-like particle according to any one of claims 1 to 4.

7. Use of the bacteria-like particles according to any one of claims 1 to 5 in the preparation of Bacillus anthracis vaccines.

8. Use of the fusion protein according to claim 6 in the preparation of Bacillus anthracis vaccine.

9. A Bacillus anthracis vaccine, characterized in that: The bacterial-like particles include any one of claims 1 to 5.

10. Use of the bacteria-like particle according to any one of claims 1 to 5, or the fusion protein according to claim 6, or the Bacillus anthracis vaccine according to claim 9 in the preparation of a medicament for treating or preventing a disease infected with Bacillus anthracis.